215 related articles for article (PubMed ID: 34632444)
1. A mouse model for the study of anti-tumor T cell responses in Kras-driven lung adenocarcinoma.
Fitzgerald B; Connolly KA; Cui C; Fagerberg E; Mariuzza DL; Hornick NI; Foster GG; William I; Cheung JF; Joshi NS
Cell Rep Methods; 2021 Sep; 1(5):. PubMed ID: 34632444
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase Cι mediates immunosuppression in lung adenocarcinoma.
Yin N; Liu Y; Weems C; Shreeder B; Lou Y; Knutson KL; Murray NR; Fields AP
Sci Transl Med; 2022 Nov; 14(671):eabq5931. PubMed ID: 36383684
[TBL] [Abstract][Full Text] [Related]
3. Impaired Cytolytic Activity and Loss of Clonal Neoantigens in Elderly Patients With Lung Adenocarcinoma.
Gong Z; Jia Q; Chen J; Diao X; Gao J; Wang X; Zhu B
J Thorac Oncol; 2019 May; 14(5):857-866. PubMed ID: 30768970
[TBL] [Abstract][Full Text] [Related]
4. Exosomal circZNF451 restrains anti-PD1 treatment in lung adenocarcinoma via polarizing macrophages by complexing with TRIM56 and FXR1.
Gao J; Ao YQ; Zhang LX; Deng J; Wang S; Wang HK; Jiang JH; Ding JY
J Exp Clin Cancer Res; 2022 Oct; 41(1):295. PubMed ID: 36209117
[TBL] [Abstract][Full Text] [Related]
5. EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z; Chen J; Ren D; Zhang J; Yang Y; Zhang H; Mao B; Ma H
Aging (Albany NY); 2020 Dec; 13(1):598-618. PubMed ID: 33288738
[TBL] [Abstract][Full Text] [Related]
6. Inducible de novo expression of neoantigens in tumor cells and mice.
Damo M; Fitzgerald B; Lu Y; Nader M; William I; Cheung JF; Connolly KA; Foster GG; Akama-Garren E; Lee DY; Chang GP; Gocheva V; Schmidt LM; Boileve A; Wilson JH; Cui C; Monroy I; Gokare P; Cabeceiras P; Jacks T; Joshi NS
Nat Biotechnol; 2021 Jan; 39(1):64-73. PubMed ID: 32719479
[TBL] [Abstract][Full Text] [Related]
7. Low-dose anti-VEGFR2 therapy promotes anti-tumor immunity in lung adenocarcinoma by down-regulating the expression of layilin on tumor-infiltrating CD8
Yang B; Deng B; Jiao XD; Qin BD; Lu Y; Zhang W; Guo Y; Chen S; Li D; Li B; Zang YS
Cell Oncol (Dordr); 2022 Dec; 45(6):1297-1309. PubMed ID: 36260222
[TBL] [Abstract][Full Text] [Related]
8. MAX transcriptionally enhances PD-L1 to inhibit CD8+ T cell-mediated killing of lung adenocarcinoma cells.
Huang D; Wang X; Qian Y; Wu J; Chen B; Zhang D; Dong F; Li Y
Cell Immunol; 2023 Apr; 386():104706. PubMed ID: 36931054
[TBL] [Abstract][Full Text] [Related]
9. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
10. Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner.
Muramatsu T; Noguchi T; Sugiyama D; Kanada Y; Fujimaki K; Ito S; Gotoh M; Nishikawa H
Int Immunol; 2021 Jan; 33(1):39-48. PubMed ID: 32729901
[TBL] [Abstract][Full Text] [Related]
11. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
12. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
13. SMARCA4 mutations in KRAS-mutant lung adenocarcinoma: a multi-cohort analysis.
Liu L; Ahmed T; Petty WJ; Grant S; Ruiz J; Lycan TW; Topaloglu U; Chou PC; Miller LD; Hawkins GA; Alexander-Miller MA; O'Neill SS; Powell BL; D'Agostino RB; Munden RF; Pasche B; Zhang W
Mol Oncol; 2021 Feb; 15(2):462-472. PubMed ID: 33107184
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
15. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
16. Inhibitor of Differentiation-1 Sustains Mutant
Román M; López I; Guruceaga E; Baraibar I; Ecay M; Collantes M; Nadal E; Vallejo A; Cadenas S; Miguel ME; Jang JH; Martin-Uriz PS; Castro-Labrador L; Vilas-Zornoza A; Lara-Astiaso D; Ponz-Sarvise M; Rolfo C; Santos ES; Raez LE; Taverna S; Behrens C; Weder W; Wistuba II; Vicent S; Gil-Bazo I
Cancer Res; 2019 Feb; 79(3):625-638. PubMed ID: 30563891
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma.
Nokin MJ; Darbo E; Travert C; Drogat B; Lacouture A; San José S; Cabrera N; Turcq B; Prouzet-Mauleon V; Falcone M; Villanueva A; Wang H; Herfs M; Mosteiro M; Jänne PA; Pujol JL; Maraver A; Barbacid M; Nadal E; Santamaría D; Ambrogio C
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32759499
[TBL] [Abstract][Full Text] [Related]
18. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
19. PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes.
Feng B; Pan B; Huang J; Du Y; Wang X; Wu J; Ma R; Shen B; Huang G; Feng J
Cancer Lett; 2023 Jul; 565():216224. PubMed ID: 37196909
[TBL] [Abstract][Full Text] [Related]
20. A robust CD8
Feng J; Xu L; Zhang S; Geng L; Zhang T; Yu Y; Yuan R; He Y; Nan Z; Lin M; Guo H
Front Immunol; 2022; 13():993187. PubMed ID: 36119068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]